We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ZVRA market cap is 499.23M. The company's latest EPS is USD -1.9296 and P/E is -4.73.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 3.43M | 4.45M | 3.7M | 12.04M | 20.4M |
| Operating Income | -20.49M | -23.8M | -27.31M | -15.42M | -5.36M |
| Net Income | -16.62M | -19.93M | -33.23M | -35.74M | -3.1M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 13.29M | 28.65M | 10.46M | 27.46M | 23.61M |
| Operating Income | -5.61M | 7.73M | -42.51M | -49.6M | -87M |
| Net Income | -12.76M | -62.9M | -41.54M | -46.05M | -105.51M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 151.28M | 144.41M | 191.55M | 178.13M | 172.71M |
| Total Liabilities | 102.47M | 111.93M | 121.78M | 138.46M | 131.69M |
| Total Equity | 48.82M | 32.48M | 69.77M | 39.67M | 41.02M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 11.21M | 132.94M | 115.53M | 172.33M | 178.13M |
| Total Liabilities | 77.62M | 5.82M | 29.72M | 110.46M | 138.46M |
| Total Equity | -66.41M | 127.12M | 85.81M | 61.86M | 39.67M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -16.17M | -35.27M | -53.42M | -69.67M | -8.22M |
| Investing | 14.79M | 14.66M | -16.69M | -22.16M | 10.54M |
| Financing | 1.22M | 16.55M | 81.31M | 82.11M | 1.61M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -1.94M | 10.44M | -18.72M | -33.54M | -69.67M |
| Investing | -33k | -15.52M | -36.72M | -17.39M | -22.16M |
| Financing | 2.74M | 113.11M | 8.35M | 28.46M | 82.11M |
| Market Cap | 499.23M |
| Price to Earnings Ratio | -4.73 |
| Price to Sales Ratio | 21.12 |
| Price to Cash Ratio | 14.76 |
| Price to Book Ratio | 12.57 |
| Dividend Yield | - |
| Shares Outstanding | 54.68M |
| Average Volume (1 week) | 768.76k |
| Average Volume (1 Month) | 622.59k |
| 52 Week Change | 84.07% |
| 52 Week High | 9.76 |
| 52 Week Low | 4.20 |
| Spread (Intraday) | 0.36 (3.79%) |
| Company Name | Zevra Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.kempharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
